Artivion (AORT) Stifel 2025 Healthcare Conference summary

Strategic focus and innovation pipeline

• Refined strategy to focus exclusively on cardiac and vascular surgeons treating the aorta, divesting non-core assets and acquiring differentiated aortic technologies over the past decade.

• Completed four major transactions since 2016, including acquisitions of On-X, Jotec, and Ascyrus, and a partnership with EndoSpan, building a comprehensive aortic product portfolio.

• Current innovation pipeline includes seven PMAs, with a plan to launch a new high-margin aortic technology every two years in the U.S. and Japan.

• No immediate need for further acquisitions, but will remain opportunistic as market opportunities arise.

Product performance and market expansion

• AMDS has driven significant growth in the aortic stent graft line, with 31% organic growth in Q3, and is seen as market-expanding by enabling more centers to treat acute type A patients quickly.

• AMDS adoption is supported by strong clinical data, reducing mortality in malperfusion patients from 30% to 10%, and is accessible to a broader range of surgeons compared to alternatives.

• On-X mechanical heart valve business has achieved over 20% growth in recent quarters, supported by new clinical data showing survival advantages over tissue valves in patients under 65.

• New reimbursement codes (MS-DRG 209) further support AMDS adoption by improving device reimbursement and easing hospital value analysis processes.

Financial outlook and operational priorities

• Long-term guidance targets double-digit revenue growth and EBITDA growth at twice the revenue rate, with recent quarters exceeding these targets.

• Gross margin expansion is underway, driven by the mix shift toward high-margin aortic products, with a long-term goal of reaching 70% gross margin.

• SG&A leverage is expected to continue, with only modest increases in sales force and targeted investments in clinical support as new products launch.

• R&D spending will rise with the Artisan trial, but gross margin gains provide flexibility to maintain EBITDA growth targets.

• Balance sheet priorities include preparing for the EndoSpan acquisition and AMDS milestone payments, followed by aggressive debt reduction as cash flow improves.